Promedior Stock

promedior.comHealthcareFounded: 2006Funding to Date: $76MM

Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.

Register for Details

For more details on financing and valuation for Promedior, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Promedior.

Register Today

Team

Management Team

Richard Jack Ph.D
President, Chief Scientific Officer & Chief Operating Officer
Renu Gupta
Chief Medical Officer
W. Scott Willett Ph.D
Vice President of Biopharmaceutical Development
Nancy Thomason
Chairman
Jason Lettmann
Chief Executive Officer & Board Member
Kieran McCarthy
Vice President of Business Development

Board Members

Geert-Jan Mulder MD
Forbion
Jason Lettmann
Paul Goldenheim MD
Howard Weisman
Nancy Thomason
Augustine Lawlor
John Friedman JD
Easton Capital Investment Group

Other companies like Promedior in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B